| Literature DB >> 31087001 |
Belén Adiego-Pérez1, Paola Randazzo2, Jean Marc Daran2, René Verwaal3, Johannes A Roubos3, Pascale Daran-Lapujade2, John van der Oost1.
Abstract
Microbial production of chemical compounds often requires highly engineered microbial cell factories. During the last years, CRISPR-Cas nucleases have been repurposed as powerful tools for genome editing. Here, we briefly review the most frequently used CRISPR-Cas tools and describe some of their applications. We describe the progress made with respect to CRISPR-based multiplex genome editing of industrial bacteria and eukaryotic microorganisms. We also review the state of the art in terms of gene expression regulation using CRISPRi and CRISPRa. Finally, we summarize the pillars for efficient multiplexed genome editing and present our view on future developments and applications of CRISPR-Cas tools for multiplex genome editing. © FEMS 2019.Entities:
Keywords: CRISPR-Cas; Cas12a; Cas9; cell factories; genome editing; multiplex
Mesh:
Year: 2019 PMID: 31087001 PMCID: PMC6522427 DOI: 10.1093/femsle/fnz086
Source DB: PubMed Journal: FEMS Microbiol Lett ISSN: 0378-1097 Impact factor: 2.742
Characteristics of the most commonly used Cas orthologues for genome editing.
| Cas9 | Cas12a | |||
|---|---|---|---|---|
| Ortholog | SpCas9 |
|
|
|
| Subtype | II-A | V-A | ||
| Organism of origin |
|
|
|
|
| Nuclease domain | HNH, RuvC | RuvC | ||
| tracrRNA | Yes | No | ||
| PAM (5′–3′) | NGG | TTTV | TTTV | TTTV |
| Size (amino acids) | 1368 | 1302 | 1307 | 1228 |
| RNA processing | No/RNaseIII | Yes/WED III | Yes/WED III | Yes/WED III |
| Minimum guide length (mature) | ∼100 nt | ∼44 nt | ||
| Reference(s) | (Deltcheva | (Zetsche, Heidenreich and Mohanraju | ||
Figure 1.(A) Cas9 and Cas12a expression and cleavage schemes. Left panel: Cas9 requires tracrRNA transcription and RNase III expression for CRISPR array transcript processing. Cas9 forms a complex with crRNA and tracrRNA and cleaves target DNA generating blunt ends. Right panel: Cas12a processes its own CRISPR array transcript to obtain individual crRNAs without the requirement of any tracrRNA or RNAse III co-expression. Cas12a stays in complex with crRNA and cleaves target DNA generating staggered ends. (B) Double strand break (DSB) repair mechanisms. DSBs can be repaired via non-homologous end joining (NHEJ), alternative non-homologous end joining repair pathways such as microhomology-mediated end joining (MMEJ), or via homologous direct recombination. NHEJ and MMEJ repair pathways can lead to the incorporation of deletions or insertions (only in case of NHEJ) in the targeted region. HDR is combined with the supplementation of donor DNA (dDNA), which can be double stranded or single stranded. dDNA can be used for insertion of long DNA sequences, deletion of genomic fragments, or introduction of single point mutations (SNPs).
Multiplexed genome editing events in industrial microorganisms using CRISPR-Cas systems.
|
| Cas nuclease tool (expression), Plasmid (replication origin)/genome integrated | Strategy for multiplexed gRNA expression/delivery (expression), plasmid (replication origin)/genome integrated | Type of donor DNA: HFs;amount/concentration | Type of modification: Number of target, editing efficiency | Reference |
|---|---|---|---|---|---|
|
| |||||
|
|
| Several sgRNA expression cassettes (constitutive),Plasmid expression | Circular dsDNA (pMB1 ori):∼300 bp | Knockouts: 2, 100%; 3, 88.3%; 4, >30% | (Feng |
|
|
| Several sgRNA expression cassettes (constitutive),Plasmid expression (pMB1 ori) | Circular dsDNA (pMB1 ori): 250–550 bp | Knockouts: 2, 97% ± 4%; 3, 47% ± 8% | (Jiang |
|
|
| Several sgRNA expression cassettes (inducible),Plasmid expression (pMB1 ori) | Linear ssDNA: 70 bp; 5 pmol | Short insertions: 2, ∼70% | (Ronda |
|
|
| Several sgRNA expression cassettes (constitutive),Plasmid expression (ColE1 ori) | Linear ssDNA: ∼89 bp; 50 pmol | Point mutations: 2, 83%; 3, 23% | (Li |
|
|
| Native-like CRISPR array (constitutive),Genome integrated | Linear dsDNA: not mentioned ;0.7 ng/µl to 2.5 µg/µl | Deletions: 2, 75% | (Jiang |
|
|
| Several sgRNA expression cassettes (constitutive),Plasmid expression (pSG5rep) | Circular dsDNA (oriT): 1 kB | Short deletions (20–34 bp): 2, 100% (4/4) | (Cobb, Wang and Zhao |
|
|
| Several sgRNA expression cassettes (constitutive),Plasmid expression (pSG5rep) | Circular dsDNA (pSG5): ∼1 kB | Deletions (768–1053 bp): 2, 29–54% | (Huang |
|
|
| Native-like CRISPR array (constitutive),Plasmid expression (pSC101 ori) | Circular dsDNA (oriE): 500 bp | Gene insertions: 3, ∼20% | (Ao |
|
|
| Native-like CRISPR array (constitutive),Plasmid expression (pSG5) | Circular dsDNA (pSG5): ∼1 kB | Knockouts: 2, 75% | (Li |
|
| |||||
|
|
| Several sgRNA expression cassettes (RNA pol III promoter, constitutive),Plasmid expression (multicopy) | Linear dsDNA: 60 bp; 12 pmols | Knockouts: 2, 100%; 6, 65% | (Mans |
|
|
| Several sgRNA expression cassettes with homology flanks to a linearized plasmid backbonePlasmid expression (multicopy) | Linear dsDNA: 500 bp; 0.6–1.54 pmols | Knockouts: 3, 64% | (Horwitz |
|
|
| Native-like CRISPR array (RNA pol III promoter, constitutive)Plasmid expression (multicopy) | Linear dsDNA: 60 bp; 12 pmols | Knockouts: 2, 100%; 4, 85% | (Swiat |
|
|
| Several sgRNA expression cassettes (RNA pol III promoter, constitutive),Plasmid expression (multicopy) | Linear ssDNA: 40 bp; 300pmols | Knockouts: 2, 91–98% | (Generoso |
|
|
| Native-like CRISPR array (RNA pol III promoter, constitutive),Plasmid expression (multicopy) | Linear dsDNA: 50 bp | Multi-gene integrations: 2, 52%; 3, 43% | (Li, Wang and Wei |
|
|
| Synthetic array of ribozyme-flanked sgRNA (RNA pol III promoter, constitutive),Plasmid expression (multicopy) | Linear dsDNA: 50 bp; 44.94 pmol | Deletions: 2, 43%; 3, 19% | (Ryan |
|
|
| Native-like crRNA-array with homology flanks to a linearized plasmid backbone (RNA pol III promoter, constitutive),Plasmid expression (multicopy) | Linear dsDNA: 50 bp; 90–120 fmols | Multi-gene integrations: 3, 91% | (Verwaal |
|
| i | Native-like crRNA-array (RNA pol III promoter, constitutive), separate expression of tracrRNA,Plasmid expression (multicopy) | Circular dsDNA, at 5’ of each spacer sequence (multicopy): 50 bp; 142 fmols | Knockouts: 3, 27–87% | (Bao |
|
|
| Synthetic crRNA-array (RNA pol III promoter), separate expression of | Linear dsDNA: 60 bp; 12 pmols | Knockouts: 2, 100%; 4, 96% | (Ferreira, |
|
|
| Several HDV ribozyme-sgRNA expression cassettes (RNA pol III promoter, constitutive),Plasmid expression (centromeric) | Linear dsDNA, barcoded: 60 bp; 55 pmols | Knockouts: 2, 65–87.5%; 3, 57.5–75%; 4, 27.5–15% | (Lee |
|
|
| Several sgRNA expression cassettes (RNA pol III promoter, constitutive),Plasmid expression (multicopy) | Linear dsDNA: 500 bp; 700 fmols | Multi-gene integrations: 3, 84% | (Ronda |
|
|
| Several sgRNA expression cassettes (RNA pol III promoter, constitutive),Plasmid expression (multicopy) | Linear dsDNA: 50 bp; 4 pmols | Multi-gene integrations: 2, 58%; 3, 30.6% | (Jakočiūnas |
|
|
| Several sgRNA expression cassettes (RNA pol III, constitutive), some target more than one site,Plasmid expression (multicopy) | Linear dsDNA: 60 bp; 26.96 pmol | Deletions: 9, 50% (only 2 transformants on plate) | (Wijsman |
|
|
| Synthetic crRNA-array (with one RNA pol III promoter for the expression of four gRNAs), gRNAs between tRNAgly sequences, Plasmid expression (multicopy) | Linear dsDNA: 50 bp; 266.9 pmol | Deletions (8 bp): 8, 86.7% | (Zhang |
|
|
| Synthetic array of ribozyme-flanked sgRNA (RNA pol II promoter, constitutive),Plasmid expression (centromeric) | Linear dsDNA: 480 bp, 1.6 pmols | Knockouts: 2, 2–5% | (Juergens |
|
| i | Several sgRNA expression cassettes expressed (RNA pol III promoter, constitutive),Genome integrated | Linear dsDNA: 1 kb, 1.7 pmols | Multi-gene integrations: 3, 30.56 ± 2.40% | (Wang |
|
|
| Synthetic array of ribozyme-flanked sgRNAs (RNA pol II promoter, constitutive),Plasmid expression (centromeric) | On multicopy plasmid: ∼450bp | Knockouts: 2, 36.7 ± 8.5%; 3, 19.3 ± 9.2% | (Gao |
|
|
|
| Linear dsDNA: ≥ 1 kb, 1–11 µg | Cassette integration: 2, 50% | (Pohl |
|
|
| Synthetic array of tRNA-flanked sgRNAs (RNA pol III promoter, constitutive),Plasmid expression (centromeric) | Linear ssDNA: 45 bp, 1 µmol | Multi-purpose: 3, 90% | (Nodvig |
|
|
|
| Linear dsDNA: 200 bp, 296 pmols | Knockouts: 2, 16–45%; 3, 4.2% | (Liu |
|
|
| Several sgRNA expression cassettes (RNA pol III promoter, constitutive),Plasmid expression (centromeric) | Linear dsDNA: 500 bp | Knockouts: 2, 40% | (Cao |
|
|
| Several sgRNA expression cassettes with homology flanks to a linearized plasmid backbone,Plasmid expression (multicopy) | Linear dsDNA: 1 kb, 0.6–1.54 pmols | Multi-gene integration: 3, 2.1% | (Horwitz |
|
|
| Several sgRNA expression cassettes (RNA pol III promoter, constitutive),Transient expression | Linear dsDNA: 600 bp; ∼12pmols | Knockouts: 2, 61–70%; 3, 30%; 4, 22% | (Liu |
|
|
| Synthetic array of ribozyme-flanked sgRNA (RNA pol II promoter, constitutive),Plasmid expression (centromeric) | Linear dsDNA: 60 bp; 12pmols | Knockouts: 2, 100% | (Gorter de Vries |
|
|
| Several sgRNA (ribozyme-flanked) expression cassettes (RNA pol II promoter, constitutive),Plasmid expression (centromeric) | Linear dsDNA: 1 kb; ∼400–770fmols | Knockouts: 2, 69 ± 13% | (Weninger |
|
|
|
| – | Knockouts: 2, 65–100%; 3, 15.4% | (Serif |
|
|
|
| Linear dsDNA: ∼40 bp | Knockouts by SNP: 2, 3.4–12.3% | (Foster |
|
|
| Several sgRNA expression cassettes (RNA pol III promoter, constitutive),Plasmid expression (centromeric) | – | Knockouts by disruption: 2, 20.8%; 3, 4.2% | (Shi |
#Anaeuploid.
Figure 2.Multiplexing using single gRNA expression cassettes. (A) Expression of several sgRNA cassettes from a single expression vector. (B) Expression of several sgRNA cassettes from multiple expression vectors (each harboring a different marker). (C) Expression of several sgRNA cassettes from multiple expression vectors (all harboring the same marker). (D) Transient supplementation with in vitro assembled RNPs or in vitro transcribed gRNAs.
Figure 3.Multiplexing using gRNA polycistronic cassettes. (A) Expression of gRNAs from synthetic array dependent on Csy4 processing. In this case, Csy4 has to be co-expressed. (B) Expression of gRNAs from synthetic array dependent on endoribonuclease splicing. In most of the reviewed examples, these synthetic arrays are expressed using tRNAs as RNA pol III promoters. (C) Expression of gRNAs from native-like CRISPR array dependent on Cas9, tracrRNA and RNAse III processing. (D) Expression of gRNAs from native-like CRISPR array dependent on Cas12a processing.
Multiplexed genome regulation events in industrial microorganisms using CRISPRi and CRISPRa.
|
| Cas nuclease tool (CRISPRi/CRISPRa), expression, promoter Plasmid (replication origin)/genome integrated | Strategy for multiplexed gRNA expression/delivery (expression) Plasmid (replication origin)/genome integrated | Goal | Number of targets | Reference |
|---|---|---|---|---|---|
|
| |||||
|
| d | Several sgRNA expression cassettes (constitutive)Plasmid expression (CloDF13ori) | Increase malate titer | 3 targets | (Gao |
|
| dd | Several sgRNA expression cassettes (j23119-SpeI constitutive promoter)Plasmid expression (ColE1 ori) | Proof of principle | 3 targets | (Zhang |
|
| d | Several sgRNA expression cassettes (j23119 constitutive promoter) fused to protein binding sequences (scaffold RNAs)Plasmid expression | Proof of principle. Activation of ethanol biosynthesis | 2 targets | (Dong |
|
| d | Several sgRNA expression cassettes (Pveg constitutive promoter)Genome integrated | Increase N-acetylglucosamine titer | 3 targets | (Wu |
|
| d | Several sgRNA expression cassettes (j23119p constitutive promoter)Genome integrated | Proof of principle (knock-out 4 pigmented antibiotic synthesis) | 3 and 4 targets | (Zhao |
|
| d | Several sgRNA expression cassettes (P | Proof of principle | 2 targets | (Tan |
|
| d | Several sgRNA expression cassettes (P | Increase aminoacid production | 3 targets | (Cleto |
|
| d | Several sgRNA expression cassettes (P | Increase GlcNAc titer | 3 targets | (Wu |
|
| d | Several sgRNA expression cassettes (PL31 constitutive promoter)Genome integrated | Reduction of PHB and glycogen accumulation during nitrogen starvation | 4 targets | (Yao |
|
| d | Several sgRNA expression cassettes (PL22 constitutive promoter)Genome integrated | Carbon flux re-direction for production of fatty alcohols | 6 targets | (Kaczmarzyk |
|
| dd | Native-like CRISPR array ( | Proof of principle (knock-out 3 pigmented antibiotic synthesis) | 3 targets | (Li |
|
| |||||
|
| dCas9-VPR (CRISPRi and CRISPRa)Plasmid expression (centromeric) | TEF1p-tRNA-sgRNA-tRNA (constitutive)Plasmid expression (centromeric) | Increase 2,3-butanediol titer | 5 targets (4 interference, 1 activation) | (Deaner, Holzman and Alper |
|
| d | Several sgRNA (with RNA scaffolds) expression cassettes (SNR52p constitutive RNA pol III promoter)Plasmid expression (centromeric) | Proof of principle, obtention of different violacein biosynthetic pathway products | 3 targets | (Zalatan |
|
| d | Several sgRNA and gRNA in synthetic array between Csy4 recognition sites (TEF1p RNA pol II constitutive promoter)Plasmid expression | Increase β-carotene production | 3 targets (1 activation, 1 interference and 1 deletion) | (Lian |
|
| d | Several sgRNA expression cassettes (RPR1-tRNAgly,RNA pol III constitutive promoter)Plasmid expression (centromeric) | Increase ethyl acetate production | 6 targets (4 genes) | (Löbs |
|
| d | Several sgRNA expression cassettes (SCR1-tRNAgly RNA pol III constitutive promoter)Plasmid expression | Increase HR by repression of the NHEJ machinery | 3 targets (2 genes) | (Schwartz |
|
| d | Synthetic array of ribozyme-flanked sgRNAs (Gal1p, RNA pol II inducible promoter)Plasmid expression (centromeric) | Proof of principle | 2 targets | (Deaner, Mejia and Alper |
|
| d | Synthetic array of ribozyme-flanked sgRNAs (TEF1p, RNA pol II constitutive promoter)Plasmid expression (centromeric) | Proof of principle | 4 targets | (Deaner, Mejia and Alper |
|
| d | Several sgRNA expression cassettes (SCR1-tRNAgly RNA pol III constitutive promoter)Plasmid expression (centromeric) | Proof of principle, decrease protodeoxy-violaceinic acid | 3 targets | (Zhang |